Barclays Capital, UBS Investment Bank, Piper Jaffray
For IPO Boutique's "scale of 1 to 5" BUY rating on Liposcience, Inc., and our comprehensive analysis, click the "Buy Market Research" link.
About Liposcience, Inc. (adapted from Liposcience, Inc. prospectus): LipoScience is an in vitro diagnostic company committed to advancing patient care in cardiovascular, metabolic and other diseases using their proprietary technology platform based on nuclear magnetic resonance, or NMR. LipoScience's first diagnostic test, the NMR LipoProfile test, is cleared by the U.S. Food and Drug Administration, or FDA, for use in their clinical laboratory and directly measures the number of low density lipoprotein, or LDL, particles for use in managing cardiovascular disease risk.
This description is adapted from Liposcience prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus..
Share this IPO Profile:
IPO Boutique aggregates information on public companies and private companies, such as Liposcience "LPDX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.